Glycomine
San Francisco, US · Founded 2014 · 7 known investors
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
Founders & leadership
CS
Christopher StarrNamed on SEC filing
PC
Peter C.M. McWilliamsNamed on SEC filing
AR
Agnes RafalkoNamed on SEC filing
Board
GC
Giacomo ChiesiBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$4.9M disclosed across 1 round · 2016
▶$4.9MraisedNov 2016 · 15 investors · BiotechnologyRule 506(b)
▶$4.9MraisedNov 2016 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher StarrDirector
- Peter C.M. McWilliamsDirector
- Agnes RafalkoExecutive Officer, Director
- Giacomo ChiesiDirector
- Offering amount
- $12.6M
- Amount sold
- $4.9M
- Minimum investment
- $10K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Glycomine do?
- Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
- Who are Glycomine's investors?
- Glycomine's investors include Advent Life Sciences, Chiesi Ventures, CTI Life Sciences Fund L.P., Remiges Ventures, Inc., RiverVest Venture Partners, Sanderling Ventures, Sanofi Ventures.
- How much funding has Glycomine raised?
- Glycomine has disclosed $4.9M raised across 1 round.
- Where is Glycomine headquartered?
- Glycomine is headquartered in San Francisco, US.